Claudéte J. Valduga

Author

Claudéte J. Valduga

Also Known As

C Valduga, C. J. VALDUGA, C. J. Valduga, C. Valduga, C.J. Valduga, Claudete J Valduga, Claudete J. Valduga, Claudete Justina Valduga, ClaudÉTe J. Valduga, Claudéte J. Valduga

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Universidade de São Paulo Anhanguera-Uniderp University Instituto Butantan Universidade Federal de Santa Maria Universidade Federal de São Paulo

About

Claudéte J. Valduga is an author at Universidade de São Paulo specializing in pharmacology, medicine, and engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	600
2	Engineering	7	7	429
3	Biomedical Engineering	3	3	255
4	Biochemistry	2	2	99
5	Biomolecular Engineering	1	1	26

Claudéte J. Valduga

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Gut Bacteria Products Prevent AKI Induced by Ischemia-Reperfusion Vinícius Andrade‐Oliveira, Mariane Tami Amano, Matheus Corrêa-Costa, Journal of the American Society of Nephrology	2015	483
Recent advances in selenocyclofunctionalization reactions Nicola Petragnani, Hélio A. Stefani, Claudéte J. Valduga Tetrahedron Organic ChemistryStereoselective SynthesisChemistryAsymmetric CatalysisRecent Advances	2001	159
Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies Debora Garcia Rodrigues, Durvanei Augusto Maria, Denise C. Fernandes, Cancer Chemotherapy and Pharmacology Lipid PreparationNanomedicinePharmaceutical ScienceEngineeringVivo Studies	2005	122
Paclitaxel associated with cholesterol-rich nanoemulsions promotes atherosclerosis regression in the rabbit Raul Cavalcante Maranhão, Elaine Rufo Tavares, A.F. Padoveze, Atherosclerosis InflammationNanomedicineAtherosclerosis RegressionCholesterol-rich NanoemulsionsEngineering	2008	91
Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study Luís A. Pires, Roberto Hegg, Claudéte J. Valduga, Cancer Chemotherapy and Pharmacology NanoparticlesNanomedicineEngineeringCholesterol-rich NanoparticlesMedicine	2008	80
Use of a cholesterol-rich microemulsion that binds to low-density lipoprotein receptors as vehicle for etoposide Claudéte J. Valduga, Denise C. Fernandes, Ana Cristina Lo Prete, Journal of Pharmacy and Pharmacology Lipid PreparationEtoposide OleateOxysterolBiochemistryMedicine	2003	73
Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin’s and non-Hodgkin’s lymphoma and a preliminary study on the toxicity of etoposide associated with LDE Ketlin V. Pinheiro, Vânia Hungria, Elisabeth Salvatori Ficker, Cancer Chemotherapy and Pharmacology Lipid AnalysisPlasma KineticsMedicinePathologyMicroemulsion	2005	70
Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro Marcelo Maia Pinheiro, Caroline Lais Stoppa, Claudéte J. Valduga, European Journal of Pharmaceutical Sciences InflammationThrombopoiesisAutoimmune DiseaseSitagliptin InhibitLymphocyte Development	2017	70
Plasma kinetics and uptake by the tumor of a cholesterol-rich microemulsion (LDE) associated to etoposide oleate in patients with ovarian carcinoma Carolina Heitmann Mares Azevedo, Jesus Paula Carvalho, Claudéte J. Valduga, Gynecologic Oncology OncologyPlasma KineticsOxysterolMedicineCholesterol-rich Microemulsion	2005	68
The Use of K-10/Ultrasound in the Selective Synthesis of Unsymmetrical β-Enamino Ketones Claudéte J. Valduga Synthesis EngineeringOrganic ChemistryStereoselective SynthesisUltrasoundUnsymmetrical β-Enamino Ketones	1998	56

Page 1